Clinical trial
Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated…
NCT00291876 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00291876 |
|---|---|
| Title | Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule |
| Official title | Double-blind Randomized Study to Evaluate the Immunogenicity and Reactogenicity of Two Different Lots of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Containing 1440 EL.U of Antigen Per mL and Injected According to a 0, 12 Month Schedule in Healthy Adult Volunteers |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis A |
| Intervention type | Biological |
| Interventions | Havrix™ |
| Enrollment | 135 |
| Start date | Jan 1, 2004 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Feb 15, 2006 |
| Last update posted | Nov 29, 2017 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: